CORD Webinar 2: When Innovation Rewrites the Pathway
From Canadian Experience to Phase 2 Readiness
How can Phase 2 RDDS help Canada anticipate the pathway consequences of new rare and precision therapies – so that screening, diagnosis, eligibility, expertise, delivery, patient choice, monitoring and learning do not have to be rebuilt after each access decision?
Speakers:
- Kim Steele, Cystic Fibrosis Canada
- Susi Vander Wyk, Cure SMA Canada
- Audrey Belouin, Canadian Association of Pompe (TBC)




